Regulators in EU, Japan and US take steps to facilitate development of new antibiotics
EMA, PMDA and FDA align data requirements and agree on areas of convergence
The European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the United States' Food and Drug Administration (FDA) have agreed to align their data requirements for certain aspects of the clinical development of new antibiotics in order to stimulate the development of new treatments to fight antimicrobial resistance and protect global public health.
Representatives from the three regulatory agencies met in Vienna on 26-27 April 2017 and discussed recommendations for the design of clinical trials that test new treatments for certain types of bacterial infections, including infections caused by multi-drug resistant organisms. They identified a number of areas where the data requirements in the three regions could be streamlined.
EMA, PMDA, and FDA will be working to update their guidance documents respectively. While the updates are ongoing, they will provide advice to individual medicine developers in line with the agreements reached.
This tripartite meeting in Vienna followed an initial meeting that took place at EMA in September 2016 where the agencies discussed regulatory approaches for the evaluation of new antibacterial agents.
Stimulating and facilitating the development of new antibiotics, in particular those targeting multidrug-resistant pathogens, is one of the three pillars in EMA’s approach and European Commission's priorities to fight antimicrobial resistance.
Responsible use of existing antibiotics both in humans and animals to limit the development of resistance and preserve the efficacy of medicines for future generations, and the collection of robust data on antibiotic consumption, in particular in animals, to inform antimicrobial policies are the other two pillars.
- Second tripartite meeting held between EMA, PMDA and FDA to discuss regulatory approaches for the evaluation of antibacterial agents (26-27/4/2017)
- Tripartite meeting between EMA, PMDA and FDA on regulatory approaches for the evaluation of antibacterial agents (1-2/9/2016)
- Antimicrobial resistance
- Partners and networks: United States
- Partners and networks: Japan
Latest News from
Rule of law in Poland and Hungary has worsened17/01/2020 12:05:00
The EU’s discussions with Poland and Hungary have not yet led these countries to realign with the EU’s founding values, Parliament warned on Thursday.
Parliament supports European Green Deal and pushes for even higher ambitions16/01/2020 15:25:00
MEPs support the European Green Deal, but highlight challenges, including ensuring a just and inclusive transition and the need for high interim targets.
Brexit: MEPs concerned about citizens' rights16/01/2020 13:25:00
Parliament highlights that assurances are needed on the protection of citizens’ rights to ensure its consent to the Withdrawal Agreement.
Meeting between President von der Leyen and Leo Varadkar, Taoiseach of Ireland16/01/2020 11:48:00
Remarks made at the joint press point (15 January 2020).
Trade/WTO: EU, U.S. and Japan agree on new ways to strengthen global rules on industrial subsidies15/01/2020 13:25:00
In a Joint Statement, representatives of the European Union, the United States and Japan announced their agreement to strengthen existing rules on industrial subsidies and condemned forced technology transfers practices.
EC steps up protection of European intellectual property in global markets10/01/2020 15:20:00
The EC has published the latest report on protection & enforcement of Intellectual Property Rights (IPR) in third countries. IPR infringements worldwide cost European firms €bns in lost revenue and put thousands of jobs at risk. The report identifies three groups of countries on which the EU will focus its action.
Speech by President von der Leyen at the LSE on 'Old friends, new beginnings: building another future for the EU-UK partnership'09/01/2020 12:10:00
In 1950, before our Union was formed, the UK, Italy and Germany were among the ten most populous countries in the world. Today, only one of those is in the top 20.
Eurojust becomes an Agency07/01/2020 12:05:00
Eurojust heralds a new phase in its development, as it officially becomes the European Agency for Criminal Justice Cooperation, with the application of the Eurojust Regulation as the new legal basis.
ESMA extends recognition decisions for 3 UK CCPs in the event of a no-deal Brexit24/12/2019 10:25:00
The European Securities and Markets Authority (ESMA) has announced that it has extended the recognition decisions for the 3 central counterparties (CCPs) established in the UK to reflect the extension of the expiry date of the Implementing Decision (EU) 2018/2031 of the EC on the equivalence of the UK CCP legal framework.